Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-1 expression
i
Other names:
Programmed Cell Death Protein 1, CD279, SLEB2, PD-1, Programmed cell death 1, PDCD1, Systemic Lupus Erythematosus Susceptibility 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5133
Related biomarkers:
Expression
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PD-1 expression
Bladder Cancer
PD-1 expression
Bladder Cancer
cisplatin
Sensitive: C3 – Early Trials
cisplatin
Sensitive
:
C3
cisplatin
Sensitive: C3 – Early Trials
cisplatin
Sensitive
:
C3
PD-1 expression
Urothelial Cancer
PD-1 expression
Urothelial Cancer
pembrolizumab + GSK3359609
Sensitive: C3 – Early Trials
pembrolizumab + GSK3359609
Sensitive
:
C3
pembrolizumab + GSK3359609
Sensitive: C3 – Early Trials
pembrolizumab + GSK3359609
Sensitive
:
C3
PD-1 expression
Renal Cell Carcinoma
PD-1 expression
Renal Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
PD-1 expression
Renal Cell Carcinoma
PD-1 expression
Renal Cell Carcinoma
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
PD-1 expression
Merkel Cell Carcinoma
PD-1 expression
Merkel Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
PD-1 expression
Sarcoma
PD-1 expression
Sarcoma
nivolumab + NKTR-214
Sensitive: C3 – Early Trials
nivolumab + NKTR-214
Sensitive
:
C3
nivolumab + NKTR-214
Sensitive: C3 – Early Trials
nivolumab + NKTR-214
Sensitive
:
C3
PD-1 expression
Cutaneous Melanoma
PD-1 expression
Cutaneous Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
PD-1 expression
Esophageal Squamous Cell Carcinoma
PD-1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
PD-1 expression
Gastric Cancer
PD-1 expression
Gastric Cancer
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login